Shukaib Arslan, M.D.

800-826-4673
Shukaib Arslan, M.D.
Hematologist-Oncologist
4.8 (71 RATINGS)
Clinical Expertise
Acute Leukemias
Allogeneic Hematopoietic Cell Transplant
Research Area
Post-transplant Relapse
GVHD
Donor Selection
Languages
Urdu
Appointments
Assistant Professor, Division Of Leukemia, Department Of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Shukaib Arslan, M.D., earned his medical degree from King Edward Medical University, a prestigious and renowned medical institution in Pakistan. Dr. Arslan completed his residency in Internal Medicine from Wayne State University in Detroit, MI before pursuing a Hematology-Oncology fellowship at Michigan State University and then fellowship in Bone Marrow Transplant at City of Hope National Medical Center. Due to his stellar performance in the ABIM Hematology Boards exam, he was invited to serve on the ABIM Hematology standard setting committee. 
 
Dr. Arslan’s passion of taking care of patients with hematological malignancies is driven from his personal family experience and finds it extremely rewarding. He carries the finest interpersonal skills and believes in multidisciplinary approach to taking care of complex hematological disorders. He engages with patients and their families so they have better understanding of their condition and available therapies to make informed decisions. 
 
Dr. Arslan’s clinical and research interests center on donor identification, therapy of post-transplant relapse of acute leukemia, treatment of graft versus host disease (GVHD) as well as outcomes of alternative donor transplant. Dr. Arslan is currently the principal investigator for clinical trials including cellular therapy and therapies for GVHD. Dr. Arslan is also participating as co-investigator in several studies involving novel therapies for acute leukemia in upfront and relapsed setting. His research also focuses on treatment of complications from ABO incompatible allogeneic hematopoietic cell transplantation such as pure red cell aplasia. 
 
Dr. Arslan also has special interest in donor identification for transplant and serves on the Donor Selection Committee in the department of Hematology and Hematopoietic Cell transplant. Donor selection is a highly specialized process where physicians identify the best donors for patients to improve outcomes. This process considers the analysis of detailed HLA typing of the patient and potential donors as well as ABO blood group typing, CMV serostatus, age, gender, and HLA antibodies. 
 
Dr. Arslan has authored multiple articles in peer reviewed journals and book chapters and regularly presents his work in national and international meetings. He serves as a member of CIBMTR Chronic Leukemia Working Committee.
Location
Education & Experience
Board Certifications

  • 2018, BLS/ACLS

  • 2018, Medical Oncology, American Board of Internal Medicine

  • 2018, Hematology, American Board of Internal Medicine

  • 2015, Professional Critical Care Support, Quality Improvement Boot Camp Training, FCCS

  • 2013, Internal Medicine, American Board of Internal Medicine

  • 2009, Educational Commission for Foreign Medical Graduates

Degrees

  • 2007, M.B.B.S., King Edward Medical University, Lahore, Pakistan

Fellowship

  • 2018-2020, Fellow, Bone Marrow and Blood Stem Cell Transplant, City of Hope, Duarte, CA

  • 2015-2018, Fellow, Hematology-Oncology, Michigan State University, Ascension St. John Providence Hospital, Southfield, MI

  • 2015-2018, Visiting Fellow Hematology-Oncology, Bone Marrow & Stem Cell Transplant Program, Karmanos Cancer Institute, and subspecialty oncology clinics, Detroit, MI

  • 2017, Visiting Fellow in Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

  • 2016, Visiting Fellow in Stem Cell Transplant Service, Dana Farber Cancer Institute/Brigham and Women Hospital, Harvard Medical School, Boston, MA

Residency

  • 2010-2013, Internal Medicine Residency, Wayne State University,
    Detroit Medical Center, Detroit, MI

Professional Experience

  • 2020-present, Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2017-2018, Clinical Instructor, Michigan State University, East Lansing, MI

  • 2014-2015, Assistant Professor, Internal Medicine, University of
    Arkansas for Medical Science, Little Rock, AR

  • 2014-2015, Hospitalist, Myeloma Institute of Research and Therapy, University of Arkansas for Medical Science, Little Rock, AR

  • 2013-2014, Hospitalist Internal Medicine, Academic Internal Medicine Specialists, Southfield, Ml

  • 2011-2011, Research Assistant, Massey Cancer Center, Virginia Common Wealth University, Richmond, VA

  • 2009, Externship and Research Elective, Department of Preventive Cardiology, University of Pennsylvania, Philadelphia, PA

Research
Lab Members
Dr. Arslan’s clinical and research interests center on donor identification, therapies for post-transplant relapse of acute leukemia, treatment of graft versus host disease (GVHD) as well as outcomes of alternative donor transplant. Dr. Arslan is currently the principal investigator of a number of clinical trials including cellular therapy and therapies for GVHD. One of these studies is evaluating the role of multi-tumor antigen specific T-cells for prevention and treatment of relapse of acute myeloid leukemia in post-transplant setting. Other studies involve use of novel agents for prevention and treatment of GVHD. Dr. Arslan is participating as co-investigator in several studies involving novel therapies for acute leukemia in upfront and relapsed setting. His research also focuses on treatment of complications from ABO incompatible allogeneic hematopoietic cell transplantation such as pure red cell aplasia. 
 
Dr. Arslan also has special interest in donor identification for transplant and serves on the Donor Selection Committee in the department of Hematology and Hematopoietic Cell transplant. Donor selection is a highly specialized process where physicians identify the best donors for patients to improve outcomes. This process takes into account the analysis of detailed HLA typing of the patient and potential donors as well as ABO blood group typing, CMV serostatus, age, gender, and HLA antibodies. Dr. Arslan is also studying the role of second degree haploidentical donor transplants in comparison with transplant from first degree family members. 
Awards & Memberships
Awards

  • 2013, Official Photographer Research Day SGH 2013

  • 2006, Official Photographer, KAPS exhibition

  • 2006, First Position in Photography in Fourth Annual KAPS Exhibition

  • 2005, College Photography for College Magazine, KEMCOL

  • 2004, Second Position in Photography, 2nd Annual KAPS exhibition

Memberships

  • American College of Physicians

  • American Society of Clinical Oncology

  • American Society of Hematology

  • American Society for Blood and Marrow Transplantation

Publications
  • Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930. PMID: 31816059; PMCID: PMC6963254.
  • Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AS, Marcucci G, Pullarkat V. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929. Epub ahead of print. PMID: 32628327.
  • Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 May 26;4(10):2308-2316. doi: 10.1182/bloodadvances.2019001381. PMID: 32453836; PMCID: PMC7252553.
  • Arslan S, Nakamura R. Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?". Curr Hematol Malig Rep. 2020 Aug;15(4):305-315. doi: 10.1007/s11899-020-00573-6. PMID: 32222884.
  • Allen J, Wang J, Zolotarskaya OY, Sule A, Mohammad S, Arslan S, Wynne KJ, Yang H, Valerie K. PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer. J Control Release. 2020 May 10;321:36-48. doi: 10.1016/j.jconrel.2020.02.003. Epub 2020 Feb 3. PMID: 32027939.
  • Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):556-560.e2. doi: 10.1016/j.clml.2020.03.004. Epub 2020 Mar 19. PMID: 32291234.
  • Arslan S, Litzow MR, Cummins NW, Rizza SA, Badley AD, Navarro W, Hashmi SK. Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biol Blood Marrow Transplant. 2019 Aug;25(8):e260-e267. doi: 10.1016/j.bbmt.2019.03.021. Epub 2019 Mar 26. PMID: 30926447; PMCID: PMC7144878.
  • Arslan S, Zhang J, Dhakal P, Moran J, Naidoo N, Lombardi J, Pullarkat V, Stein AS, Marcucci G, Yaghmour G, Bhatt VR, Fathi AT, Aldoss I. Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia. Am J Hematol. 2020 Nov 23. doi: 10.1002/ajh.26057. Epub ahead of print. PMID: 33227142.
  • Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2020 Dec 1. doi: 10.1002/cncr.33340. Epub ahead of print. PMID: 33259056.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
4.9
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.8
Know important info medical history
4.8
Spend enough time with you
4.8
Recommend this provider office
4.7
Rate provider 0-10
Reviews
02/06/23
Good - Verified patient
01/21/23
Dr Arslan was great! - Verified patient
10/09/22
Good - Verified patient
10/09/22
Good - Verified patient
09/10/22
Good - Verified patient